National Pharmaceutical Pricing Authority directs firms to cut prices of three anti-cancer drugs

Govt. had earlier scrapped customs duty on Trastuzumab, Osimertinib and Durvalumab and also reduced GST rates on them

Updated - October 29, 2024 08:23 pm IST - NEW DELHI

Manufacturers are required to issue a price list or supplementary price list indicating changes, and submit information regarding price change to the pharma pricing regulator.

Manufacturers are required to issue a price list or supplementary price list indicating changes, and submit information regarding price change to the pharma pricing regulator. | Photo Credit: Getty Images/iStockphoto

The National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers to reduce the maximum retail price (MRP) of three anti-cancer drugs – Trastuzumab, Osimertinib and Durvalumab – in line with the government’s commitment to ensure the availability of drugs at affordable prices.   

“This is in pursuance of the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty. The Department of Revenue, Ministry of Finance, issued a notification recently reducing the customs duty on these three drugs to nil,’’ said a release issued by the Central government on Tuesday (October 29, 2024). 

Further, the Department of Revenue had issued a notification reducing the GST rates on the three drugs from 12% to 5% with effect from October 10, 2024.

“Accordingly, there should be a reduction in the MRP of these drugs in the market, and the benefits of reduced taxes and duties should be passed on to the consumers,’’ said the release.

Hence the NPPA issued the present directive. The manufacturers are required to issue a price list or supplementary price list to the dealers, State Drugs Controllers and the government indicating the changes, and submit information regarding price change to the NPPA through the relevant forms (Form-II/ Form-V). 

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.